Former Damon Runyon Clinical Investigator @BuckanovichLab and his team set out to understand why only some ovarian cancer patients respond favorably to immune checkpoint inhibitors, and found that the answer lay in the tumor microenvironment. Learn more: https://t.co/bYHAebRyd9
What if we could prevent the recurrence of #ovariancancer? Through critical research, Magee-Womens Research Institute investigators like Dr. Ronald Buckanovich are giving women with cancer new hope. #OvarianCancerAwarenessMonth
Make a gift today: https://t.co/C1qDeWJtQq
Targeting therapeutic resistance and multinucleate giant cells in CCNE1-amplified HR-proficient ovarian cancer https://t.co/zLM0ADvOJh
A potential new therapeutic approach for women with hard to treat CCNE1 amplified tumors.
Very excited to share our latest paper in @ScienceTM co-led with @BcellBruno on the prevalence of intratumoral Tregs expressing NRP1 and their association with poor outcome in cancer patients. Kudos to my grad student Chris Chuckran who led this study! https://t.co/0fDweUgJhZ
.@KellyLeonPSU et al. @airdlab demonstrate that DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A. https://t.co/96zVJLPU3N
Part of the Year in Cell Biology: 2021 https://t.co/7BZrJIcFnw
#CellBio2021
It's important to be aware of the signs & symptoms of #OvarianCancer like bloating, upset stomach, frequent urination, feeling full quickly & pelvic pain. Contact your doctor if these symptoms persist for 2+ weeks. Read @Kandigyrl3's full story at https://t.co/sl8P3zPpJ8